Adimab Announces Launch of Four New Proprietary Technologies

– Heavy Chain-Only Antibody Libraries –

– Heavy Chain/Light Chain and Heavy Chain/Heavy Chain Pairing Solutions for Multispecific Antibodies –

– Fc Silencing Mutations to Attenuate Immune Signaling –

– Antibody Half-life Extension Technology –

LEBANON, N.H.–(BUSINESS WIRE)–Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced an expanded offering of proprietary technologies to aid the development of antibody and multispecific therapeutic modalities. These technologies are a result of a collaborative effort between Adimab’s Computational Biology team in Palo Alto, CA and Antibody Engineering team in Lebanon, NH to provide Adimab’s partners with end-to-end solutions for therapeutic antibodies across multiple formats.

1. Adimab has released first-generation heavy chain-only antibody (HCAb) libraries to meet the growing demand for single-domain antibodies. Designed with the aid of novel machine learning methodology trained on extensive internal data from our commercially validated synthetic human IgG libraries as well as natural VHH repertoires, the HCAb libraries aim to minimize developability risk while ensuring high sequence diversity and broad epitope coverage. Utilizing the Adimab HCAb libraries follows the same efficient workflows and timelines of our standard IgG discovery and optimization process.
2. To support multispecific antibody programs, Adimab has employed both extensive structural modeling and directed protein evolution to derive novel heterodimerization solutions both at the heavy chain/light chain interface as well as the heavy chain interface in the CH3 domain. This readily allows for the formation of an IgG-like bispecific from any two antibodies, or the flexibility to generate other multispecific therapeutic molecules.
3. Adimab has developed constant region mutations for Fc-silencing. Disabling Fc effector functions can be critical in certain therapeutic approaches and thus constitutes an important addition to our overall portfolio of Fc technologies. Adimab’s Fc-silencing mutations allow our partners to exclusively focus the therapeutic impact of their antibody on the variable domain target specificity while maintaining favorable developability properties expected of full-length antibodies.
4. Adimab has developed specific Fc engineering solutions and screening assays that enable the half-life extension of therapeutic antibodies and multispecific molecules in humans. Recent data generated in a Phase I clinical trial demonstrated an IgG half-life exceeding three months.

Adimab has filed multiple patent families to protect the proprietary nature of these technologies.

“We are excited to see our extensive investments in exploratory research translate into tangible solutions that our partners value. Antibody drug developers are increasingly demanding more from their lead candidates. Having a portfolio of solutions is an important element of ensuring our partners’ technical successes and progression of their molecules into the clinic,” said Eric Krauland, Chief Scientific Officer of Adimab.

“Our partners have complex technical needs and are seeking a competitive edge as they design and develop their programs. Our research team invests significant time and effort to expand our capabilities; however, before the launch of any Adimab technology, there needs to be a demonstrated level of quality and validation that matches our reputation,” said Guy Van Meter, Chief Business Officer of Adimab.

About Adimab

Adimab is the leading provider of therapeutic antibody discovery and engineering technologies. This includes naïve discovery from synthetic libraries in yeast or B cells (mice and humans), antibody engineering and optimization, multi-specific antibody engineering, and a portfolio of proprietary CD3 antibodies licensed non-exclusively for bispecific applications. Adimab focuses solely on its partners and not on developing an internal product pipeline. Since 2009, Adimab has partnered with more than 95 pharmaceutical and biotechnology companies, generating more than 425 therapeutic programs, 55 clinical programs, and its first approved product. The Adimab technology has been transferred and implemented at Biogen, GSK, Lilly, Merck, Novo Nordisk, and Takeda. Funded discovery partners include leading pharmaceutical companies, such as Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Regeneron, Sanofi, Takeda and others. Adimab has also partnered with many early-stage venture-backed companies, including Amagma, Cygnal, Dragonfly, iOmx, NextPoint, Pliant, Tizona, TRex Bio and others, as well as mid-size public biopharmaceutical companies such as Acceleron, Alector, Cullinan Oncology, Innovent, Jounce, Mersana, Scholar Rock, Surface Oncology, and others.

Adimab’s integrated antibody discovery and engineering platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most demanding standards for affinity, epitope coverage, species cross-reactivity, and developability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements. For more information, visit http://www.adimab.com.

Contacts

Guy Van Meter

Chief Business Officer

Adimab, LLC.

(603) 653-5775

[email protected]